A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer
1 other identifier
observational
15,000
1 country
1
Brief Summary
This study aims to establish a colorectal cancer cohort, collect clinicopathological information, collect biological samples for multi-omics testing, and perform relevant analysis, to predict the prognosis of colorectal cancer, guide the diagnosis and treatment of colorectal cancer and the formulation of health policies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
September 23, 2021
CompletedFirst Posted
Study publicly available on registry
October 21, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 9, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 9, 2022
CompletedOctober 21, 2021
March 1, 2021
1.8 years
September 23, 2021
October 7, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Disease-free survival time
For patients received radical resection of colorectal cancer, disease-free survival time is defined as time from the surgery to any recurrence of disease or death, recorded in months.
2 yeas after surgery
Secondary Outcomes (2)
Overall survival time
2 yeas after surgery
Pathological TNM stage
1 month after surgery
Interventions
Any surgery for primary tumor of colorectal cancer, including palliative resection, simple bowel stoma and exploratory surgery.
Eligibility Criteria
All patients pathologically diagnosed as colorectal cancer, and receiving any surgery of primary tumor, including palliative resection, simple enterostomy and exploratory surgery
You may qualify if:
- Pathologically diagnosed as colorectal cancer
- Receiving any surgery of primary tumor, including palliative resection, simple enterostomy and exploratory surgery
You may not qualify if:
- The patient refused to join the study
- The patient refused to collect the biological sample
- The patient refused to follow up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fudan Universitylead
Study Sites (1)
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Biospecimen
The specimens include primary tumor tissue, adjacent tissues, normal mucosa tissue, and peripheral venous blood. Tissue samples will be used for multiple omics tests, including genome, transcriptome, proteome, etc. Blood samples are used for tumor markers, immunology and other tests.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2021
First Posted
October 21, 2021
Study Start
December 1, 2020
Primary Completion
September 9, 2022
Study Completion
September 9, 2022
Last Updated
October 21, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will not share